Weekly Cisplatin-Based Chemoradiotherapy Improves RFS and OS, Although Not Statistically Significant, for Patients with Cervical Cancer and Intermediate Pathologic Risk Factors By Ogkologos - September 24, 2025 442 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NRG Oncology/GOG-263/KGOG1008 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR EMA Recommends Extension of Indications for Ribociclib to Include Use in... November 5, 2024 Pembrolizumab Improves Survival in Patients from Asia with Previously Treated Advanced... December 12, 2022 Time to get stratified January 10, 2023 Pastor Opens Homeless Shelter And Moves In To Raise Money For... December 29, 2021 Load more HOT NEWS HER2 Expression is a Determinant of Sensitivity to Trastuzumab Deruxtecan in... When Natural Disasters Strike, This Program Helps Provide Relief To People... News digest – ovarian cancer blood test, statins, spending review and... Cancer in My Community: Reducing Tobacco Use in Tunisia
